Classification of Antibiotics
Antibiotics are classified into three major stewardship categories (AWaRe framework) and can be further organized by their mechanism of action, with each class targeting specific bacterial structures or metabolic pathways.
AWaRe Stewardship Classification
The WHO's AWaRe framework provides the primary organizational structure for antibiotic classification based on resistance risk and appropriate use 1:
Access Group
- First-line empiric antibiotics for common infections
- Lower resistance potential compared to other groups
- Should be widely available, affordable, and of assured quality
- Examples: penicillins, first-generation cephalosporins, macrolides (erythromycin), clindamycin
Watch Group
- Higher resistance risk and greater toxicity concerns
- Includes highest priority critically important antimicrobials
- Requires targeted stewardship and monitoring
- Examples: fluoroquinolones, carbapenems, third/fourth-generation cephalosporins
- Key distinction: These may be first-choice for specific indications but require careful oversight
Reserve Group
- Last-resort options only for multidrug-resistant organisms
- Used when all other alternatives have failed
- Requires strict protection through stewardship programs
- Eight antibiotics total in this category
- Reserved for severe/life-threatening infections with resistant pathogens
Classification by Mechanism of Action
Antibiotics can be simultaneously classified by how they kill or inhibit bacteria 2, 3:
Cell Wall Synthesis Inhibitors
β-lactams: Penicillins, cephalosporins, carbapenems, monobactams
- Inhibit transpeptidase and DD-carboxypeptidase enzymes
- Prevent peptidoglycan cross-linking in bacterial cell wall
- Structural analogy to D-alanyl-D-alanine dipeptide 4
Glycopeptides: Vancomycin, teicoplanin
- Bind to D-alanyl-D-alanine terminus of peptidoglycan precursors
Fosfomycin: Inhibits early peptidoglycan synthesis
Protein Synthesis Inhibitors
Aminoglycosides: Bind 30S ribosomal subunit
- Cause misreading of mRNA and false protein translation 4
Macrolides: Bind 50S ribosomal subunit
Tetracyclines: Block aminoacyl-tRNA binding to 30S subunit
Lincosamides (clindamycin): Bind 50S subunit
Oxazolidinones (linezolid): Inhibit 50S ribosomal assembly
Chloramphenicol, fusidic acid: Various ribosomal targets
Nucleic Acid Synthesis Inhibitors
Fluoroquinolones: Inhibit DNA gyrase and topoisomerase IV
Rifamycins: Bind β-subunit of RNA polymerase
- Cause conformational change preventing RNA synthesis 4
Metabolic Pathway Inhibitors
- Sulfonamides/Trimethoprim (cotrimoxazole): Block folate biosynthesis pathway
Cell Membrane Disruptors
- Polymyxins: Disrupt bacterial cell membrane integrity
- Lipopeptides (daptomycin): Cause membrane depolarization
Clinical Application Framework
When selecting antibiotics, integrate both classifications:
- Start with AWaRe category appropriate for clinical setting and local resistance patterns 1
- Match mechanism of action to suspected pathogen and infection site
- Consider spectrum: Narrow-spectrum Access antibiotics preferred when pathogen known
- Escalate to Watch/Reserve only when Access options inadequate or resistance documented
Common Pitfalls to Avoid
- Using Watch antibiotics (fluoroquinolones, carbapenems) as first-line when Access options available
- Failing to de-escalate from broad to narrow spectrum once culture results available
- Ignoring local resistance patterns when selecting empiric therapy
- Prescribing Reserve antibiotics without documented multidrug resistance
The AWaRe framework should guide all empiric antibiotic selection, with mechanism-based classification informing specific drug choice within each category 1.